Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes.

Abstract:

:Microsomal P450-mediated monooxygenase activity supported by NADPH requires an interaction between flavoprotein NADPH-cytochrome P450 reductase and cytochrome P450. These proteins have been identified as the simplest system (with the inclusion of a phospholipid (PL) component) that possesses monooxygenase function; however, little is known about the organization of these proteins in the microsomal membrane. Although reductase and P450 are known to form a 1:1 functional complex, there exists a 10- to 20-fold excess of P450 over the reductase. This raises several questions including "How are the enzymes of the P450 system organized in the microsomal membrane?" and "Can one P450 enzyme affect the functional characteristics of another P450?" This review summarizes evidence supporting the potential for enzymes involved in the P450 system to interact, focusing on the interactions between reductase and P450 and interactions between multiple P450 enzymes. Studies on the aggregation characteristics of P450 as well as on rotational diffusion are detailed, with a special emphasis on the potential for P450 enzymes to produce oligomeric complexes and to suggest the environment in which P450 exists in the endoplasmic reticulum. Finally, more recent studies describing the potential for multiple P450s to exist as complexes and their effect on P450 function are presented, including studies using reconstituted systems as well as systems where two P450s are coexpressed in the presence of reductase. An understanding of the interactions among reductase and multiple P450s is important for predicting conditions where the drug disposition may be altered by the direct effects of P450-P450 complex formation. Furthermore, the potential for one P450 enzyme to affect the behavior of another P450 may be extremely important for drug screening and development, requiring metabolic screening of a drug with reconstituted systems containing multiple P450s rather than simpler systems containing only a single form.

journal_name

Pharmacol Ther

authors

Backes WL,Kelley RW

doi

10.1016/s0163-7258(03)00031-7

subject

Has Abstract

pub_date

2003-05-01 00:00:00

pages

221-33

issue

2

eissn

0163-7258

issn

1879-016X

pii

S0163725803000317

journal_volume

98

pub_type

杂志文章,评审
  • Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

    abstract::Dopamine D2 autoreceptors (D2ARs), located in somatodendritic and axon terminal compartments of dopamine (DA) neurons, function to provide a negative feedback regulatory control on DA neuron firing, DA synthesis, reuptake and release. Dysregulation of D2AR-mediated DA signaling is implicated in vulnerability to substa...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107583

    authors: Chen R,Ferris MJ,Wang S

    更新日期:2020-09-01 00:00:00

  • Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.

    abstract::Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors are a class of lipid-lowering medications, with a major activity on plasma cholesterol levels, now enjoying a vast popularity among physicians and patients. These drugs, affecting a very early and key step of sterol biosynthesis, differ to a large extent ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(93)90031-8

    authors: Sirtori CR

    更新日期:1993-12-01 00:00:00

  • Transcranial magnetic brain stimulation: therapeutic promises and scientific gaps.

    abstract::Since its commercial advent in 1985, transcranial magnetic stimulation (TMS), a technique for stimulating neurons in the cerebral cortex through the scalp, safely and with minimal discomfort, has captured the imaginations of scientists, clinicians and lay observers. Initially a laboratory tool for neurophysiologists s...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.09.003

    authors: Wassermann EM,Zimmermann T

    更新日期:2012-01-01 00:00:00

  • LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis.

    abstract::Lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1) was initially identified as the major receptor for oxidized LDL (OxLDL) in endothelial cells. Its inducible expression in macrophages and smooth muscle cell was also observed. LOX-1 is a Type II membrane protein with a typical C-type lectin structur...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(02)00236-x

    authors: Chen M,Masaki T,Sawamura T

    更新日期:2002-07-01 00:00:00

  • Metabolic suicide genes in gene therapy.

    abstract::This article reviews uses of metabolic suicide genes in gene therapy. Suicide genes encode novel nonmammalian enzymes that can convert a relatively nontoxic prodrug into a highly toxic agent. Cells genetically transduced to express such genes essentially commit metabolic suicide in the presence of the appropriate prod...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(94)90046-9

    authors: Mullen CA

    更新日期:1994-08-01 00:00:00

  • Long noncoding RNA loss in immune suppression in cancer.

    abstract::Long noncoding RNAs (lncRNAs) have multiple functions in the regulation of cellular homeostasis. In recent years, numerous studies have shown that tumor-associated lncRNAs play key roles in promoting and maintaining tumor initiation and progression by shaping the tumor microenvironment through changing tumor cell intr...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107591

    authors: Hu Q,Egranov SD,Lin C,Yang L

    更新日期:2020-09-01 00:00:00

  • Targeting peroxisome proliferator-activated receptors: A new strategy for the treatment of cardiac fibrosis.

    abstract::Cardiac fibrosis is a pathogenic factor of many cardiovascular diseases (CVD), which seriously affects people's life, and health and causes huge economic losses. Increasing evidence has shown that peroxisome proliferator-activated receptors (PPARs) can regulate the progression of cardiac fibrosis. For the first time, ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107702

    authors: Lu Q,Guo P,Guo J,Ares I,Lopez-Torres B,Martínez-Larrañaga MR,Wang X,Anadón A,Martínez MA

    更新日期:2020-10-04 00:00:00

  • Bronchial epithelium as a target for innovative treatments in asthma.

    abstract::Increasing evidence of a critical role played by the bronchial epithelium in airway homeostasis is opening new therapeutic avenues. Its unique situation at the interface with the environment suggests that the subtle regulation orchestrated by the epithelium between tolerance and specific immune response might be impai...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2013.07.008

    authors: Gras D,Chanez P,Vachier I,Petit A,Bourdin A

    更新日期:2013-12-01 00:00:00

  • Intracellular signaling pathways that regulate behavioral responses to ethanol.

    abstract::Recent evidence indicates that ethanol modulates the function of specific intracellular signaling cascades, including those that contain cyclic adenosine 3', 5'-monophosphate (cAMP)-dependent protein kinase A (PKA), protein kinase C (PKC), the tyrosine kinase Fyn, and phospholipase D (PLD). In some cases, the specific...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.07.004

    authors: Newton PM,Messing RO

    更新日期:2006-01-01 00:00:00

  • GABAB receptors as drug targets to treat gastroesophageal reflux disease.

    abstract::For many years, acid-suppressive therapy has been at the forefront of treating gastroesophageal reflux disease (GERD), yet despite the advent of the proton pump inhibitors (PPIs) some patients continue to experience persistent GERD symptoms. Therapeutic (non-surgical) options for such patients are currently limited. T...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.02.008

    authors: Lehmann A

    更新日期:2009-06-01 00:00:00

  • Endothelins and sarafotoxins: physiological regulation, receptor subtypes and transmembrane signaling.

    abstract::The endothelins and sarafotoxins are two structurally related families of potent vasoactive peptides. Although the physiological functions of these peptides are not entirely clear, the endothelins are probably involved in pathophysiological conditions such as hypertension and heart failure. This review summarizes the ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(92)90030-4

    authors: Sokolovsky M

    更新日期:1992-01-01 00:00:00

  • Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.

    abstract::The past three decades have witnessed a welcome expansion of the therapeutic armamentarium for the management of pulmonary arterial hypertension (PAH). However, against this backdrop, there have been some notable disappointments in drug development. Here we use these as case studies to emphasize the importance of info...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.04.012

    authors: Lythgoe MP,Rhodes CJ,Ghataorhe P,Attard M,Wharton J,Wilkins MR

    更新日期:2016-08-01 00:00:00

  • Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets.

    abstract::Forward Pharmacology seeks to identify small or large molecules that modulate a normal or abnormal biological process in living cells or whole organisms and historically has been responsible for the discovery of many clinically used drugs. Forward Pharmacology approaches have become particularly attractive because adv...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.03.002

    authors: Vogt A,Lazo JS

    更新日期:2005-08-01 00:00:00

  • Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.

    abstract::There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the treatment of patients with non-small cell lung cancer (NSCLC). Among them, the epidermal growth factor receptor (EGFR) TK inhibitors (TKIs) are the most extensively studied. Receptor TKIs including EGFR TKIs have shown dramat...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.03.002

    authors: Kuwano M,Sonoda K,Murakami Y,Watari K,Ono M

    更新日期:2016-05-01 00:00:00

  • Phosphorothioate oligodeoxynucleotides--anti-sense inhibitors of gene expression?

    abstract::Phosphorothioate (PS) oligodeoxynucleotides are relatively nuclease resistant, water soluble analogs of phosphodiester (PO) oligodeoxynucleotides. These molecules are chiral but still hybridize well to their RNA targets. While considered for use as in vivo anti-sense inhibitors of gene expression, their biology, espec...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(91)90032-h

    authors: Stein CA,Tonkinson JL,Yakubov L

    更新日期:1991-12-01 00:00:00

  • Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency.

    abstract::Glucose-6-phospate dehydrogenase (G6PD) deficiency is estimated to affect more than 400 million people world-wide. This X-linked genetic deficiency puts stress on red blood cells (RBC), which may be further augmented under certain pathophysiological conditions and drug treatments. These conditions can cause hemolytic ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107788

    authors: Ryan K,Tekwani BL

    更新日期:2020-12-14 00:00:00

  • Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain.

    abstract::Injury to peripheral or spinal nerves following either trauma or disease has several consequences including the development of neuropathic pain. This syndrome is often refractory against conventional analgesics; and thus, novel medicaments are desired for its treatment. Recent studies have emphasized that dysfunction ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.pharmthera.2009.03.018

    authors: Dohi T,Morita K,Kitayama T,Motoyama N,Morioka N

    更新日期:2009-07-01 00:00:00

  • The approach to understanding aromatic hydrocarbon carcinogenesis. The central role of radical cations in metabolic activation.

    abstract::Polycyclic aromatic hydrocarbons (PAH) are carcinogens requiring metabolic activation to react with cellular macromolecules, the initial event in carcinogenesis. Cytochrome P450 mediates binding of PAH to DNA by two pathways of activation. One-electron oxidation to form radical cations is the major pathway of activati...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(92)90015-r

    authors: Cavalieri EL,Rogan EG

    更新日期:1992-01-01 00:00:00

  • Molecular genetics of hepatic methionine adenosyltransferase deficiency.

    abstract::Hepatic methionine adenosyltransferase (MAT) deficiency is caused by mutations in the human MAT1A gene that abolish or reduce hepatic MAT activity that catalyzes the synthesis of S-adenosylmethionine from methionine and ATP. This genetic disorder is characterized by isolated persistent hypermethioninemia in the absenc...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(99)00047-9

    authors: Chou JY

    更新日期:2000-01-01 00:00:00

  • Monoclonal antibodies as probes of structure, function and isoenzyme forms of the type II regulatory subunit of cyclic AMP-dependent protein kinase.

    abstract::We have attempted to review studies which have utilized monoclonal antibodies in the analysis of various aspects of type II cAMP-dependent protein kinase. It is readily apparent that the monoclonal antibodies directed against RII can be used in a number of ways to assess the structure and function of this protein. Mon...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(85)90059-2

    authors: Mumby MC,Weldon SL,Scott CW,Taylor SS

    更新日期:1985-01-01 00:00:00

  • The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.

    abstract::Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological e...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.02.005

    authors: Miller AM,Liew FY

    更新日期:2011-08-01 00:00:00

  • Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans.

    abstract::Evidence has accumulated indicating that the interaction between NO and the autonomic nervous system plays an important role in cardiovascular regulation, not only in experimental animals, but also in humans. NO interacts with the autonomic nervous system both at the central level and peripherally. In this review, we ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2004.11.009

    authors: Sartori C,Lepori M,Scherrer U

    更新日期:2005-05-01 00:00:00

  • The role of the leukemia inhibitory factor receptor in neuroprotective signaling.

    abstract::Several neurotropic cytokines relay their signaling through the leukemia inhibitory factor receptor. This 190kDa subunit couples with the 130kDa gp130 subunit to transduce intracellular signaling in neurons and oligodendrocytes that leads to expression of genes associated with neurosurvival. Moreover, activation of th...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.08.008

    authors: Davis SM,Pennypacker KR

    更新日期:2018-03-01 00:00:00

  • The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications.

    abstract::Thoracic aortic aneurysms (TAAs) are a potential life-threatening disease with limited pharmacological treatment options. Current treatment options are aimed at lowering aortic hemodynamic stress, predominantly with β-adrenoceptor blockers. Increasing evidence supports a role for the renin-angiotensin system (RAS) in ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.04.002

    authors: Moltzer E,Essers J,van Esch JH,Roos-Hesselink JW,Danser AH

    更新日期:2011-07-01 00:00:00

  • Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system.

    abstract::Cyclooxygenase (COX) enzymes, or prostaglandin-endoperoxide synthases (PTGS), are heme-containing bis-oxygenases that catalyze the first committed reaction in metabolism of arachidonic acid (AA) to the potent lipid mediators, prostanoids and thromboxanes. Two isozymes of COX enzymes (COX-1 and COX-2) have been identif...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.04.011

    authors: Hewett SJ,Bell SC,Hewett JA

    更新日期:2006-11-01 00:00:00

  • Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.

    abstract::The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107628

    authors: Wang JJ,Edin ML,Zeldin DC,Li C,Wang DW,Chen C

    更新日期:2020-11-01 00:00:00

  • Clinical attrition due to biased preclinical assessments of potential efficacy.

    abstract::Unless it is carefully controlled, bias often distorts the results of clinical trials, usually exaggerating the magnitude of true efficacy. For that reason, procedures to limit bias have been mandated by the FDA when assessing efficacy in clinical trials. The present review shows that the effects of bias in preclinica...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.05.002

    authors: Lindner MD

    更新日期:2007-07-01 00:00:00

  • The structure and mechanism of bacterial type I signal peptidases. A novel antibiotic target.

    abstract::Type I signal peptidases are essential membrane-bound serine proteases that function to cleave the amino-terminal signal peptide extension from proteins that are translocated across biological membranes. The bacterial signal peptidases are unique serine proteases that utilize a Ser/Lys catalytic dyad mechanism in plac...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1016/s0163-7258(00)00064-4

    authors: Paetzel M,Dalbey RE,Strynadka NC

    更新日期:2000-07-01 00:00:00

  • Dietary manipulation of platelet function.

    abstract::Activated platelets contribute to plaque formation within blood vessels in the early and late stages of atherogenesis, and therefore they have been proposed as risk factor for cardiovascular disease. Anti-platelet drugs, such as aspirin, are now the most prescribed pharmacological treatment in Europe. Certain dietary ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.05.008

    authors: Bachmair EM,Ostertag LM,Zhang X,de Roos B

    更新日期:2014-11-01 00:00:00

  • KIT as a therapeutic target for non-oncological diseases.

    abstract::KIT is a receptor tyrosine kinase that after binding to its ligand stem cell factor activates signaling cascades linked to biological processes such as proliferation, differentiation, migration and cell survival. Based on studies performed on SCF and/or KIT mutant animals that presented anemia, sterility, and/or pigme...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.12.008

    authors: Martinez-Anton A,Gras D,Bourdin A,Dubreuil P,Chanez P

    更新日期:2019-05-01 00:00:00